Pharma's Market
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Why Amazon Rules Retail
- Wave of Debt Payments Facing US Government
- The Social Media Gaming Threat
- China Eastern to Complete Shanghai Air Buy by End '09
- Paul: Audit the Fed
- JAL Slides to Record Low on Bankruptcy Jitters
- Gold Will Collapse Like Oil Did in 2008: Charts
- Prepare For Large Decline In Stocks, Next Year?
- Lyondell Urged to Consider Reliance Takeover Offer
- Can Murdoch Help Bing Challenge Google and Shift the Content Equation?
- HP's Mark Hurd
- HP Comes in As Expected; Is It Time to Buy?
- 9 Stocks That Play Rising Water Costs: Strategists
- Weis' Deal Likely Won't Change Big Money Contracts
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
- How Many US Consumers Will Shop this Weekend?
- Tuesday's Heavy Dose of Data to Dictate 'Risk' Behavior
- Obama says Boosting US Jobs is Top Priority
- More Consumers Giving 'Black Friday' the Cold Shoulder
- Prepare For Large Decline In Stocks, Next Year?
- Appeals Court Denies Microsoft's Alcatel Petition
- HP Comes in As Expected; Is It Time to Buy?
- Cramer: What Monday’s Housing Number Really Means
- Why the Dollar Will Likely Stay Weak for Some Time
PHARMA'S MARKET VIDEO
Cholesterol Drug Battle: Niaspan vs. Zetia 
16 Nov 2009
Cardiologist Grades Cholesterol Drug Study 16 Nov 2009
Merck's Cholesterol Drugs Under Pressure 16 Nov 2009
Cholesterol Drug Battle: Merck vs. Abbott Labs 16 Nov 2009
Cholesterol Drug Battle 16 Nov 2009
Novo Nordisk CEO on Diabetes Epidemic 13 Nov 2009
RSS FEED
Text Size 
CNBC Correspondent
In case you weren't aware, tomorrow is "World Osteoporosis Day" or WOD, for short, as the International Osteoporosis Foundation hilariously refers to it, but biotech Amgen won't be celebrating the occasion.
 |
Had the FDA today approved AMGN's [AMGN
Loading...
()
] twice-a-year injectable bone drug, Prolia, the champagne corks would have been popping. But instead, the FDA handed Amgen the dreaded CRL.
What's that, you ask? CRL replaced the old approvable letters. The terminology was a bit confusing. People would see the word approvable and think, "Oh, good!" But it wasn't.
Approvable was a euphemism for delay as in, "We might approve the drug sometime down the road, if/when you dot an i or cross a t and/or provide us some more information/data."
This morning Amgen announced that the FDA wants more details on how the company will monitor patients once Prolia is on the market. And the agency requested Amgen do another study to see if Prolia works at preventing osteoporosis.
It was the second CRL to be disclosed this morning. Novartis [NVS
Loading...
()
] got one, too. NVS' is for a one-a-day inhaler to treat COPD, or what some more broadly refer to as smoker's cough.
Novartis would only say that the agency wants more info on the dosing. Sometimes companies fully disclose what's contained in a CRL, sometimes they reveal some or a little bit of information and other times nothing at all. I suspect that both companies got their respective CRLs last Friday or over the weekend since both press releases hit the wires bright and early.
Biopharma companies, it seems, have gotten so used to getting an approvable letter or CRL, that they all reach into the drawer and pull out the same press release template and just fill in the blanks. For example, Amgen says it "will work with the FDA to determine the appropriate next steps...." And Novartis says it "will continue to work closely with the FDA...." I guess Novartis must have a cozier relationship with regulators than Amgen. Kidding. Kidding!
P.S. Please tune in to CNBC's "Power Lunch" at noon ET for my exclusive interview with Pfizer [PFE
Loading...
()
] Chairman and CEO Jeff Kindler after the company reports earnings Tuesday morning.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes